Risedronate prevents new vertebral fractures in postmenopausal women at high risk

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 2, 2003, Pages 542-549

  Watts, Nelson B ^a,h   Josse, Robert G ^b   Hamdy, Ronald C ^c   Hughes, Rodney A ^d   Manhart, Michael D ^e   Barton, Ian ^e   Calligeros, Danny ^f   Felsenberg, Dieter ^g  

^a UNIVERSITY OF CINCINNATI   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c EAST TENNESSEE STATE UNIVERSITY   (United States)

^d ST PETER S HOSPITAL   (United Kingdom)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^f Medical Diagnostics Australia   (Australia)

^g FREIE UNIVERSITÄT BERLIN   (Germany)

^h NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISEDRONIC ACID;

ADULT; AGE; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

AGED; CALCIUM CHANNEL BLOCKERS; ETIDRONIC ACID; FEMALE; HUMANS; INCIDENCE; OSTEOPOROSIS, POSTMENOPAUSAL; RECURRENCE; RISK FACTORS; SPINAL FRACTURES;

EID: 0037326110     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020400     Document Type: Article

References (41)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
2. Ross PD 1997 Clinical consequences of vertebral fractures. Am J Med 103:30S-43S
3. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR 1998 The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793-800
4. Ettinger B, Black DM, Nevitt MC, Rundle AC, Cauley JA, Cummings SR, Genant HK, and The Study of Osteoporotic Fractures Research Group 1992 Contribution of vertebral deformities to chronic back pain and disability. J Bone Miner Res 7:449-556
5. Melton III LJ 1997 Epidemiology of spinal osteoporosis. Spine 22(24 Suppl):2S-11S
6. Nevitt MC, Ross PD, Palermo L, Musliner T, Genant HK, Thompson DE, for The Fracture Intervention Trial Research Group 1999 Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. Bone 25:613-619
7. Ross PD, Davis JW, Epstein RS, Wasnich RD 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919-923
8. Klotzbuecher CM, Ross PD, Landsman PB, Abbott III TA, Berger M 2000 Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
9. Burger H, van Daele PLA, Algra D, Hofman A, Grobbee DE, Schütte HE, Birkenhäger JC, Pols HAP 1994 Vertebral deformities as predictors of non-vertebral fractures. BMJ 309:991-992
10. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR, for the Study of Osteoporotic Fractures Research Group 1999 Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 14:821-828
11. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E 2001 Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323
12. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut III CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344-1352
13. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
14. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster J-Y, for the Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 344:333-340
15. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster J-Y, for the BMD-MN Study Group 2000 Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85:1895-1900
16. Hooper M, Ebeling P, Roberts A, D'Emden M, Nicholson G, Crusan C, Wenderoth D, Ethgen D, for the Australian Risedronate Prevention Study Group 1999 Risedronate prevents bone loss in early postmenopausal women. Calcif Tissue Int 64(Suppl 1):S69
17. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP, for the European Corticosteroid-Induced Osteoporosis Treatment Study 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15:1006-1013
18. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenward M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA 1999 Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42:2309-2318
19. Melton III LJ, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL 1993 Prevalence and incidence of vertebral deformities. Osteoporos Int 3:113-119
20. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
21. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston Jr CC, Lindsay R 1998 Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-489
22. Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD 1993 Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 3:120-126
23. Melton III LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227-1233
24. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. Lancet 341:72-75
25. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254
26. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592
27. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236
28. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
29. Watts N, Bockman R, Smith C, Li Z, Eastell R, Pack S, Lindsay R 2000 BMD change explains only a fraction of the observed fracture risk reduction in risedronate-treated patients. Osteoporos Int 11(Suppl 2):S203
30. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D, for the PROOF Study Group 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267-276
31. Li Z, Meredith MP, Hoseyni MS 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175-3188
32. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10
33. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289
34. Jeng GT, Scott JR, Burmeister LF 1995 A comparison of meta-analytic results using literature vs. individual patient data. Paternal cell immunization for recurrent miscarriage. JAMA 274:830-836
35. Duchateau L, Pignon JP, Bijnens L, Bertin S, Bourhis J, Sylvester R 2001 Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. Control Clin Trials 22:538-547
36. Whitehead A 2002 Meta-analysis of controlled clinical trials. Chichester, West Sussex, UK: John Wiley & Sons, Ltd.; 6-7
37. Borah B, Dufresne TE, Chmielewski PA, Prenger MC, Manhart MD 2002 Risedronate (RIS) preserves trabecular architecture in early postmenopausal women in just 1 year: a paired biopsy study using 3-D MICROCT. Osteoporos Int 13(Suppl 1):S25
38. Eastell R, Barton I, Hannon RA, Garnero P, Chines A, Pack S, Delmas PD 2001 Antifracture efficacy of risedronate: prediction by change in bone resorption markers. J Bone Miner Res 16(Suppl 1):S163
39. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs Jr RW, Dequeker J, Favus M, for the Alendronate Phase III Osteoporosis Treatment Study Group 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
40. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
41. Hoseyni MS, Ritter-Hrncirik C, Li Z, Eastell R, Miller PD 2000 Impact of different morphometric criteria for evaluation of incident vertebral deformities. Osteoporos Int 13(Suppl 1):S77